Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04725760
Other study ID # 2020-WIFR-8313
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date September 30, 2022

Study information

Verified date January 2021
Source Wicab
Contact Patricia Grant, Ph.D.
Phone 312-447-3234
Email pgrant@wicab.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the effectiveness and safety of the BrainPort® Vision Pro, an electronic oral assistive device, in the performance of daily tasks by French persons who have residual vision limited to light perception or less in both eyes.


Recruitment information / eligibility

Status Recruiting
Enrollment 125
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years and older
Eligibility Inclusion Criteria: 1. 8 years of age or older 2. Diagnosis of profound blindness with residual vision limited to a perception of light or lower in both eyes. 3. Minimum post 12 months diagnosis of blindness 4. Previously completed conventional rehabilitation such as orientation and mobility training with a cane or guide dog. 5. Ability to be read and to understand the documentation and procedures of the study. 6. Ability to provide feedback on the use of the BrainPort Vision Pro device. 7. Ability to use basic computer and/or other technologies. 8. Willing and able to answer all questionnaires, carry out telephone follow-ups, undergo device training and carry out all study procedures, after having passed the orientation phase with the device. 9. Participant or his legal representative willing and able to sign informed consent. Exclusion Criteria: 1. Ongoing oral disorders determined on the basis of the participant's medical history and/or by an examination of the oral cavity by a dental specialist. 2. History of tongue damage resulting in sensitivity problems or impaired language. 3. Visible open sores, herpes, abrasions, blisters or rashes on the tongue or numbness of the tongue. 4. Piercings on the tongue. 5. Planned or recent oral surgery (in the last 3 months) and/or dental care (excluding oral check-ups or routine scaling). 6. Known neuropathy of the language or sensory system. 7. History of seizures or epilepsy. 8. Pregnant woman, willing to be pregnant or lactating. Women of childbearing age should consent to the use of appropriate contraception to avoid pregnancy during the study period. 9. Implanted medical devices (e.g., pacemaker, deep brain stimulation device, cochlear implant). 10. Any hearing impairment that prevents you from hearing the device's announcements. 11. Cognitive impairment detected on the basis of medical history and/or during a cognitive impairment telephone interview. 12. Expected or ongoing participation in another clinical trial or any research that may interfere with this study. 13. Known allergy to nickel, gold or a stainless-steel component. 14. Any health condition that may interfere with the study's evaluations. 15. A person unable to assemble the device and/or interpret the device's signals or who refuses to continue to participate in the study after passing the initial training phase with the device. 16. Person deemed unfit to participate in the study by the lead investigator for any other previously cited reason. 17. Adults who do not have the ability to provide valid informed consent (under legal protection)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BrainPort Vision Pro
Ten hours of training over 3 to 5 days, followed by autonomous use of the device. It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months.

Locations

Country Name City State
France University Hospital La Timone Marseille
France CHU de Montpellier Montpellier
France University Hospital of Nantes Nantes
France Institut Aramav Nimes
France Fondation hospitalière Sainte-Marie Paris
France Necker-Enfants Malades Hospital Paris
France Hôpitaux Universitaires de Strasbourg, Reference Center for Rare Disorders in Ophthalmic Genetics Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
Wicab

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Function Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision. 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability) Baseline
Primary Visual Function Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability) 3 months
Primary Visual Function Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability) 6 months
Primary Visual Function Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability) 12 months
Secondary Object recognition Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded. Baseline
Secondary Character identification High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented. Baseline
Secondary Orientation and mobility tasks This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways. Baseline
Secondary Object recognition Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded. 3 months
Secondary Character identification High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented. 3 months
Secondary Orientation and mobility tasks This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways. 3 months
Secondary Object recognition Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded. 6 months
Secondary Character identification High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented. 6 months
Secondary Orientation and mobility tasks This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways. 6 months
Secondary Object recognition Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded. 12 months
Secondary Character identification High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented. 12 months
Secondary Orientation and mobility tasks This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways. 12 months
Secondary Impact of Vision Impairment-Very Low Vision Quality of Life Scale A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life. Baseline
Secondary Impact of Vision Impairment-Very Low Vision Quality of Life Scale, A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life. 3 months
Secondary Impact of Vision Impairment-Very Low Vision Quality of Life Scale, A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life. 6 months
Secondary Impact of Vision Impairment-Very Low Vision Quality of Life Scale, A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life. 12 months
Secondary Adverse events related to device or study procedures Safety 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02393118 - A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury N/A
Terminated NCT00262509 - Emergency Egress and Information System for Persons With Vision Loss N/A
Terminated NCT00691444 - Blind Child Melatonin Treatment Study N/A
Recruiting NCT06237829 - Testing Tactile Aids With Blind Subjects N/A
Completed NCT00829036 - Wayfinding Information Access System for People With Vision Loss N/A
Completed NCT01488786 - A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind N/A
Completed NCT02643238 - Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation N/A
Recruiting NCT00403143 - Do Blue-Blocking Lenses Block Blue Colour From Our Lives? N/A
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Recruiting NCT02983370 - Development of a Cortical Visual Neuroprosthesis for the Blind N/A
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
Completed NCT01109576 - Workshops for Veterans With Vision and Hearing Loss Phase 0
Completed NCT00920231 - Computer Vision System for the Blind Veteran Phase 1
Terminated NCT00795236 - Melatonin Studies of Totally Blind Children N/A
Terminated NCT00634972 - Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Phase 4
Enrolling by invitation NCT06364605 - MySpace: the Role of Vision in Representing Space N/A
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Not yet recruiting NCT05806684 - Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3